SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX) saw its shares climb 4.5% in after-hours trading on Tuesday after the prescription savings platform reported second-quarter revenue that exceeded analyst expectations, despite providing weaker-than-anticipated guidance.
The company posted revenue of $200.6 million for Q2, slightly above the consensus estimate of $200.47 million and up 6% YoY. Adjusted earnings per share came in at $0.08, matching analyst projections.
GoodRx's prescription transactions revenue, its largest segment, increased 7% YoY to $146.7 million, driven by an 8% rise in Monthly Active Consumers.
"We're proud of the progress we're making against our key priorities, especially when it comes to strengthening our relationships with retail and PBM partners, scaling our offerings around brand medications, and deepening our relationships with patients," said Scott Wagner, Interim Chief Executive Officer of GoodRx.
However, the company's outlook fell short of expectations. For Q3, GoodRx forecasts revenue between $193 million and $197 million, below the $202.4 million analysts were anticipating. The full-year 2024 revenue guidance of $800 million to $810 million also came in at the low end of the company's previous range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.